Atlas Trials

Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma

Clinical trial NCT00055562 · COMPLETED

Trial details

NCT number
NCT00055562
Sponsor
Celgene Corporation
Status
COMPLETED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
MelanomaNeoplasm Metastasis
Start date
2003-01-01
Enrollment
274

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.